Table 2 Univariate analysis of factors associated with OS of EHC patients.

From: Biliary stenting alone versus biliary stenting combined with 125I particles intracavitary irradiation for the treatment of advanced cholangiocarcinoma

Variables

Univariate analysis

HR (95% CI)

p value

Gender (male vs. female)

1.027 (0.736–1.433)

0.876

Age (high vs. low)

1.049 (0.759–1.449)

0.771

Location (DCCA vs. HCCA)

0.826 (0.585–1.168)

0.279

CA19-9 (high vs. low)

1.991 (1.225–3.234)

0.005

CEA (high vs. low)

1.131 (0.804–1.591)

0.478

ALT (high vs. low)

1.225 (0.782–1.921)

0.376

AST (high vs. low)

1.188 (0.831–1.697)

0.345

ALP (high vs. low)

1.229 (0.785–1.923)

0.368

GGT (high vs. low)

1.401 (0.791–2.483)

0.248

TBIL (high vs. low)

1.914 (1.334–2.747)

<0.001

DBIL (high vs. low)

1.370 (0.976–1.924)

0.069

ALB (high vs. low)

0.764 (0.550–1.063)

0.110

PT-INR (high vs. low)

1.182 (0.826–1.691)

0.360

NC (high vs. low)

1.438 (1.032–2.003)

0.032

LC (high vs. low)

0.612 (0.381–0.984)

0.043

PLT (high vs. low)

0.878 (0.594–1.298)

0.514

CRP (high vs. low)

1.189 (0.823–1.718)

0.356

PTBS + 125I vs. PTBS

0.280 (0.193–0.406)

<0.001

  1. HCCA hilar cholangiocarcinoma, DCCA distal cholangiocarcinoma, CA19-9 carbohydrate antigen 19-9, CEA carcino-embryonic antigen, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT gamma-glutamyl transpeptidase, TBIL total bilirubin, DBIL direct bilirubin, ALB albumin, PT-INR prothrombin time-international normalized ratio, NC neutrophil count, LC lymphocyte count, PLT platelet count, CRP c-reactive protein, PTBS percutaneous transhepatic biliary stenting.
Back to article page